Transcarent
One Place for Health and Care: AI-powered health navigation and care delivery for self-insured employers and health plans
Updated 3d ago
Valuation
$3.0B
as of May 2026
Total raised
$957M
Series D (plus subsequent acquisition financing)
Est. revenue
—
Momentum
8/10
Maturity
7/10
Headcount
—
Consumer-grade healthcare navigation and care delivery for self-insured employers and health plans. The WayFinding platform uses generative/agentic AI to answer benefits questions, check symptoms, schedule care, and route 20M+ members into its own care experiences (Cancer Care, Surgery Care, Weight Health, Pharmacy Care, virtual primary care and expert medical opinion via Accolade) plus an Experience Store of third-party point solutions (mental health, fertility, diabetes, MSK) across 1,700+ employer/health-plan clients, with the pitch of better experience, higher quality, and lower total cost of care.
Revenue model
B2B contracts with self-insured employers and health plans; PEPM/subscription navigation fees plus at-risk and value-based pricing (Transcarent historically priced fully at-risk, paid only when it delivers savings), episode-of-care bundles for surgery/cancer/weight health, and transparent pharmacy benefit fees.
No combined figure disclosed post take-private. A ~$500M 2025 estimate can be derived (Accolade reported $414M revenue in fiscal 2024 per public filings, +18% YoY; Transcarent standalone estimated ~$85M ARR by GetLatka) but no credible source confirms a combined number, so estimateUSD is set to null (fact-check, July 2026). Headcount also unverifiable: the profile's 1,000 figure is not supported by any credible source; third-party trackers diverge widely (PitchBook ~454, GetLatka ~551, LeadIQ ~645, Tracxn ~776 as of spring 2026), so headcountEstimate is set to null.
Stated: become the "One Place for Health and Care" — consolidate fragmented point solutions into a single AI-driven front door, using the Accolade merger to combine Transcarent's AI navigation and at-risk care experiences with Accolade's advocacy, expert medical opinion, and virtual primary care base. Inferred: roll-up-and-platform play — use scale (20M+ members) and Glen Tullman's capital network (General Catalyst, 62 Ventures) to buy distribution, then deepen monetization per member by cross-selling surgery/cancer/weight/pharmacy episodes and displacing legacy navigators and PBM opacity (successive SmithRx transparent-PBM integrations in April and June 2026). The mid-2026 hiring of an ex-Amazon/One Medical CPO (Anjali Jameson) and a job board dominated by LLM/ML engineering, data science, and data-integration roles signal a decisive shift from post-merger integration to AI product velocity — positioning WayFinding as the AI operating layer for employer health benefits, with a likely eventual IPO of the combined company (Tullman has publicly said he has no interest in selling but sees IPO as an option).
Scale and data: 20M+ members and 1,700+ employer/health-plan clients post-Accolade — the largest footprint among navigators — feeding a proprietary memory/personalization engine (Total Recall); an integrated stack (navigation + advocacy + virtual care + care experiences + transparent pharmacy) that point solutions can't match; at-risk pricing contracts that are hard for asset-light competitors to underwrite; direct contracts with marquee health systems; and Tullman's founder brand and investor network for capital access.
Agentic AI as the primary care-navigation interface (voice scheduling, autonomous booking, proactive next-best-action)
highWayFinding 2.0 launch at CES 2026 added voice AI scheduling, symptom checking, and the Total Recall Memory Engine; execs frame AI agents as replacing call-center navigation economics, and mid-2026 job postings are dominated by Senior ML Engineer - LLM, Senior Data Scientist, and AI-platform roles.
Disrupting the PBM stack with transparent pharmacy
highSuccessive SmithRx integrations (April and June 2026) embed the Drug Pathways Engine and transparent PBM options directly into WayFinding, attacking legacy PBM spread pricing — the largest employer cost pain point.
Deep claims/benefits data unification as the platform substrate
mediumData Integration Engineer and data-platform postings, plus the Total Recall Memory Engine, indicate a build-out to fuse Accolade advocacy data, claims, and benefits feeds into one member graph — the prerequisite for both AI personalization and at-risk underwriting.
AI-first internal operations as a margin play
mediumRoles like 'Senior Manager, AI and Leadership Enablement' and the self-description as an 'AI-first organization' show Transcarent is automating its own advocacy/service workforce, converting Accolade's labor-heavy cost base into software margins ahead of any IPO.
Expansion from employers into health plans as channel customers
mediumCompany consistently markets to 'employers and health plans' with a dedicated health-plans offering; Accolade brought health-plan distribution, and plan partnerships scale membership faster than employer-by-employer sales.
Further consolidation via M&A to become the single employer health platform
mediumThe Accolade take-private, financing from General Catalyst/62 Ventures, and Tullman's 'One Place for Health and Care' ambition signal appetite to acquire point solutions rather than partner; no new acquisition announced since, so pace may wait on integration.
Eventual IPO of the combined company
lowTullman says he has 'no interest' in selling but explicitly keeps IPO open and runs the company 'like a public company'; $3B valuation, $957M raised, JPMorgan debt to refinance, and growth-stage investors needing liquidity make a public exit the visible endgame once integration and profitability stabilize.
Jun 2026
Appointed Anjali Jameson (ex-Amazon/One Medical, Rally Health, Apple) as Chief Product Officer to drive agentic-AI product strategy
Jun 2026
Deepened SmithRx integration, embedding the Drug Pathways Engine and prescription drug cost intelligence directly into the WayFinding experience
May 2026
Ranked No. 12 on the 2026 CNBC Disruptor 50; disclosed $3B valuation and $957M total raised
Apr 2026
Announced SmithRx as integrated transparent-PBM partner in the Pharmacy Care Experience for drug pricing transparency
Jan 2026
Launched WayFinding 2.0 at CES: agentic voice AI scheduling, symptom checking, Total Recall Memory Engine, and Personalized Health Path; Tullman talked up AI doctors and partnerships at JPM Healthcare Conference
Jul 2025
Jennifer Trzepacz joined as Chief People Officer to lead post-merger org integration
Jun 2025
Named to the 2025 CNBC Disruptor 50 list
Apr 2025
Completed the Accolade merger and took it private; combined company serves 20M+ members and 1,700+ employer/health-plan clients
Jan 2025
Announced agreement to acquire Accolade (NASDAQ: ACCD) for $7.03/share, ~$621M equity value, financed by General Catalyst, 62 Ventures, and JPMorgan-led debt
Glen TullmanFounder & CEO
Serial health-tech entrepreneur: former CEO of Livongo (sold to Teladoc for ~$18.5B) and Allscripts; managing partner of 7wireVentures and founder of 62 Ventures. Has run four public companies and led three IPOs; says he runs Transcarent 'like a public company.'
Snezana MahonPresident
PharmD; former COO of Transcarent and previously GM/VP at Evernorth (Express Scripts), deep pharmacy and clinical-program operations background.
Anjali JamesonChief Product Officer
Joined June 2026 to lead product strategy for the agentic-AI WayFinding platform; previously led product/technology at Amazon One Medical, Rally Health, UnitedHealth Group, Zipongo, and Apple (mobile commerce).
Stephanie PengChief Financial Officer
Finance leader overseeing the combined Transcarent-Accolade P&L after the 2025 take-private merger.
Praful KaulChief Technology Officer
Engineering leader responsible for the WayFinding agentic AI platform and Total Recall Memory Engine.
Alan RogaChief Clinical Officer
MD, FACEP; emergency physician and former Teladoc executive (founded Stat Health/StatDoc), leads clinical quality across care experiences.
Laurie McGrawChief Commercial Officer
Former SVP at the American Medical Association and President of Allscripts, leads employer and health-plan sales.
- Largest member base in health navigation (20M+ members, 1,700+ clients) after the $621M Accolade take-private
- Full-stack offering: AI navigation plus owned care experiences (cancer, surgery, weight, pharmacy, virtual primary care, expert medical opinion) and an Experience Store of curated point solutions
- Fast, credible agentic-AI product cadence (WayFinding 2.0 with voice scheduling, symptom checking, Total Recall Memory Engine at CES 2026; two SmithRx pharmacy integrations by mid-2026)
- Deep-pocketed backers (General Catalyst, Kinnevik, 7wireVentures, 62 Ventures) and ~$957M raised; $3B valuation as of May 2026 (No. 12 on CNBC Disruptor 50)
- Proven leadership bench deepened in 2026: Glen Tullman's Livongo playbook plus new CPO Anjali Jameson (Amazon/One Medical, Apple, UnitedHealth) and execs from Express Scripts, Teladoc, AMA
- Aligned at-risk/value-based pricing resonates with cost-pressured self-insured employers
- AI-first internal operations: hiring shows dedicated enterprise AI enablement and LLM engineering functions, supporting margin leverage over call-center-based rivals
- Integration risk: absorbing Accolade, a larger, historically unprofitable public company (~$414M FY2024 revenue, persistent losses), strains culture, tech stacks, and margins
- Combined entity likely still unprofitable with debt from JPMorgan-led acquisition financing on the balance sheet
- Navigation ROI is notoriously hard to prove; employer churn risk if savings guarantees don't materialize
- Opaque financials post take-private make traction hard to verify; revenue mix still skewed to legacy Accolade advocacy services; third-party headcount estimates diverge widely (550-1,000+), hinting at post-merger attrition or restructuring
- Brand confusion during re-platforming of Accolade clients onto WayFinding
- Employer benefits budgets tightening; consolidation fatigue and RFP scrutiny of navigation vendors' claimed savings
- Well-funded competition: Included Health (Doctor on Demand/Grand Rounds scale), Quantum Health, Personify Health, and payer-owned navigation offerings
- Agentic AI in clinical triage/scheduling invites regulatory and liability exposure (symptom checking, care steerage) as FTC/state scrutiny of health AI grows
- Debt service plus at-risk contracts create margin squeeze if utilization or savings targets miss
- Coverage disruption from government pullback: millions losing coverage shrinks employer-sponsored membership pools even as Tullman frames it as a tech-adoption catalyst
- Key-person dependence on Glen Tullman for capital, vision, and sales credibility
Competitors
Technologies
Partnerships
Intelligence profile re-researched for Transcarent.
SmithRx Brings Prescription Drug Cost Intelligence Into Benefits Navigation Through Transcarent Partnership - PR Newswire (PR Newswire)
Initial intelligence profile created for Transcarent.
- cnbc.com/2026/05/19/transcarent-cnbc-disruptor-50-ranking.html
- transcarent.com/press-releases/transcarent-appoints-anjali-jameson-as-ch
- businesswire.com/news/home/20260603504536/en/Transcarent-Appoints-Anjali
- prnewswire.com/news-releases/smithrx-brings-prescription-drug-cost-intel
- businesswire.com/news/home/20260424837294/en/Transcarent-Expands-WayFind
- transcarent.com/press-releases/transcarent-completes-merger-with-accolad
- transcarent.com/press-releases/transcarent-adds-scheduling-symptom-check
- cnbc.com/2025/04/08/digital-health-startup-transcarent-completes-621m-ac
- fiercehealthcare.com/ai-and-machine-learning/transcarent-builds-out-agen
- mobihealthnews.com/news/transcarent-finalizes-merger-accolade
- medcitynews.com/2024/05/glen-tullman-has-no-interest-in-selling-transcar
- mobihealthnews.com/news/qa-glen-tullman-discusses-tech-adoption-millions
- boards.greenhouse.io/transcarent
- job-boards.greenhouse.io/transcarent/jobs/5802895004
- transcarent.com/leadership
- transcarent.com/press-releases/transcarent-raises-usd126-million-series-
- statnews.com/2024/05/02/glen-tullman-transcarent-health-tech-secures-126
- getlatka.com/companies/transcarent.com
- sec.gov/Archives/edgar/data/0001481646/000114036125000544/ny20041213x1_e
- businesswire.com/news/home/20240502320693/en/Transcarent-Raises-$126-Mil
- fiercehealthcare.com/digital-health/transcarent-completes-621m-merger-ac
- transcarent.com/contact-us